Shopping Cart
- Remove All
- Your shopping cart is currently empty
ADR-925, an active chelated iron metabolite of dexrazoxane, has the ability to protect neonatal rat cardiomyocytes from doxorubicin-induced injury.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $1,120 | In Stock | |
5 mg | $2,250 | In Stock | |
10 mg | $2,970 | In Stock | |
25 mg | $4,490 | In Stock | |
50 mg | $5,970 | In Stock |
Description | ADR-925, an active chelated iron metabolite of dexrazoxane, has the ability to protect neonatal rat cardiomyocytes from doxorubicin-induced injury. |
In vivo | METHODS: ADR-925 (ICRF 198) (88 mg/kg, intraperitoneal injection, 30 minutes before doxorubicin injection, once a week, 12 times) was administered to mice to observe the protective effect of ADR-925 against the lethal effects of mice. RESULTS In animals pretreated with ADR559, there was partial protection against the lethal effects of doxorubicin. [2] |
Alias | ICRF-198, ICRF198, ICRF 198, ADR925, ADR 925 |
Molecular Weight | 304.3 |
Formula | C11H20N4O6 |
Cas No. | 75459-34-6 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.